,20 Biologics targeting IL-17, for instance ixekizumab and brodalumab, have shown excellent efficacy in treating moderate-to-severe psoriasis and are relatively well-tolerated with long-term maintenance of treatment responses.21 The gene discussed is IL17A; the disease is psoriasis.